APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for the Treatment of Refractory Gout

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for the Treatment of Refractory Gout Market Analysis and Forecast 2026-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchDrugs for the Treatment of Refractory Gout Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for the Treatment of Refractory Gout Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Drugs for the Treatment of Refractory Gout Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for the Treatment of Refractory Gout Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for the Treatment of Refractory Gout Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Drugs for the Treatment of Refractory Gout market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Drugs for the Treatment of Refractory Gout is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for the Treatment of Refractory Gout is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for the Treatment of Refractory Gout is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for the Treatment of Refractory Gout is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Drugs for the Treatment of Refractory Gout include Zhuhai Livzon Biotechnology, Sobi, Qilu Pharmaceutical, Roche, Bio-Thera Solutions, Sandoz, Pfizer, Novartis and Kiniksa Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Drugs for the Treatment of Refractory Gout, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for the Treatment of Refractory Gout, also provides the sales of main regions and countries. Of the upcoming market potential for Drugs for the Treatment of Refractory Gout, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for the Treatment of Refractory Gout sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for the Treatment of Refractory Gout market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Drugs for the Treatment of Refractory Gout sales, projected growth trends, production technology, application and end-user industry.

Drugs for the Treatment of Refractory Gout Segment by Company

Zhuhai Livzon Biotechnology

Sobi

Qilu Pharmaceutical

Roche

Bio-Thera Solutions

Sandoz

Pfizer

Novartis

Kiniksa Pharmaceuticals

Horizo​​n Therapeutics

Hanwha Chemical

Fresenius Kabi

Biogen

Amgen

Drugs for the Treatment of Refractory Gout Segment by Type

Tumor Necrosis Factor Inhibitors

PEGylated Recombinant Uricase

Interleukin Inhibitors

Other

Drugs for the Treatment of Refractory Gout Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Drugs for the Treatment of Refractory Gout Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for the Treatment of Refractory Gout market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for the Treatment of Refractory Gout and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for the Treatment of Refractory Gout.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Drugs for the Treatment of Refractory Gout in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Drugs for the Treatment of Refractory Gout manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for the Treatment of Refractory Gout sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for the Treatment of Refractory Gout Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tumor Necrosis Factor Inhibitors Major Manufacturers Table 3. PEGylated Recombinant Uricase Major Manufacturers Table 4. Interleukin Inhibitors Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Drugs for the Treatment of Refractory Gout Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital and Clinic Major Manufacturers Table 8. Retail Pharmacies Major Manufacturers Table 9. Other Major Manufacturers Table 10. Drugs for the Treatment of Refractory Gout Industry Trends Table 11. Drugs for the Treatment of Refractory Gout Industry Drivers Table 12. Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges Table 13. Drugs for the Treatment of Refractory Gout Industry Restraints Table 14. Global Drugs for the Treatment of Refractory Gout Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2026) Table 18. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2027-2032) Table 19. Global Drugs for the Treatment of Refractory Gout Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2026) & (K Units) Table 21. Global Drugs for the Treatment of Refractory Gout Sales by Region (2027-2032) & (K Units) Table 22. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2021-2026) Table 23. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2027-2032) Table 24. Global Drugs for the Treatment of Refractory Gout Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Drugs for the Treatment of Refractory Gout Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Manufacturers (2021-2026) Table 28. Global Drugs for the Treatment of Refractory Gout Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Drugs for the Treatment of Refractory Gout Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Drugs for the Treatment of Refractory Gout Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Drugs for the Treatment of Refractory Gout Manufacturers, Product Type & Application Table 32. Global Drugs for the Treatment of Refractory Gout Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Drugs for the Treatment of Refractory Gout by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Drugs for the Treatment of Refractory Gout Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2026) Table 39. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2027-2032) Table 40. Global Drugs for the Treatment of Refractory Gout Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 42. Global Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 43. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2026) Table 44. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2027-2032) Table 45. Global Drugs for the Treatment of Refractory Gout Price by Type (2021-2026) & (US$/Unit) Table 46. Global Drugs for the Treatment of Refractory Gout Price by Type (2027-2032) & (US$/Unit) Table 47. Global Drugs for the Treatment of Refractory Gout Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2026) Table 51. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2027-2032) Table 52. Global Drugs for the Treatment of Refractory Gout Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 54. Global Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 55. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2026) Table 56. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2027-2032) Table 57. Global Drugs for the Treatment of Refractory Gout Price by Application (2021-2026) & (US$/Unit) Table 58. Global Drugs for the Treatment of Refractory Gout Price by Application (2027-2032) & (US$/Unit) Table 59. Zhuhai Livzon Biotechnology Company Information Table 60. Zhuhai Livzon Biotechnology Business Overview Table 61. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio Table 63. Zhuhai Livzon Biotechnology Recent Development Table 64. Sobi Company Information Table 65. Sobi Business Overview Table 66. Sobi Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Sobi Drugs for the Treatment of Refractory Gout Product Portfolio Table 68. Sobi Recent Development Table 69. Qilu Pharmaceutical Company Information Table 70. Qilu Pharmaceutical Business Overview Table 71. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio Table 73. Qilu Pharmaceutical Recent Development Table 74. Roche Company Information Table 75. Roche Business Overview Table 76. Roche Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Roche Drugs for the Treatment of Refractory Gout Product Portfolio Table 78. Roche Recent Development Table 79. Bio-Thera Solutions Company Information Table 80. Bio-Thera Solutions Business Overview Table 81. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio Table 83. Bio-Thera Solutions Recent Development Table 84. Sandoz Company Information Table 85. Sandoz Business Overview Table 86. Sandoz Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio Table 88. Sandoz Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio Table 93. Pfizer Recent Development Table 94. Novartis Company Information Table 95. Novartis Business Overview Table 96. Novartis Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Novartis Drugs for the Treatment of Refractory Gout Product Portfolio Table 98. Novartis Recent Development Table 99. Kiniksa Pharmaceuticals Company Information Table 100. Kiniksa Pharmaceuticals Business Overview Table 101. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio Table 103. Kiniksa Pharmaceuticals Recent Development Table 104. Horizo​​n Therapeutics Company Information Table 105. Horizo​​n Therapeutics Business Overview Table 106. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio Table 108. Horizo​​n Therapeutics Recent Development Table 109. Hanwha Chemical Company Information Table 110. Hanwha Chemical Business Overview Table 111. Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio Table 113. Hanwha Chemical Recent Development Table 114. Fresenius Kabi Company Information Table 115. Fresenius Kabi Business Overview Table 116. Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio Table 118. Fresenius Kabi Recent Development Table 119. Biogen Company Information Table 120. Biogen Business Overview Table 121. Biogen Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Biogen Drugs for the Treatment of Refractory Gout Product Portfolio Table 123. Biogen Recent Development Table 124. Amgen Company Information Table 125. Amgen Business Overview Table 126. Amgen Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Amgen Drugs for the Treatment of Refractory Gout Product Portfolio Table 128. Amgen Recent Development Table 129. North America Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (US$ Million) Table 130. North America Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (US$ Million) Table 131. North America Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 132. North America Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 133. North America Drugs for the Treatment of Refractory Gout Sales Price by Type (2021-2026) & (US$/Unit) Table 134. North America Drugs for the Treatment of Refractory Gout Sales Price by Type (2027-2032) & (US$/Unit) Table 135. North America Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (US$ Million) Table 136. North America Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (US$ Million) Table 137. North America Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 138. North America Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 139. North America Drugs for the Treatment of Refractory Gout Sales Price by Application (2021-2026) & (US$/Unit) Table 140. North America Drugs for the Treatment of Refractory Gout Sales Price by Application (2027-2032) & (US$/Unit) Table 141. North America Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. North America Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. North America Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 145. North America Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 146. North America Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 147. North America Drugs for the Treatment of Refractory Gout Sales Price by Country (2021-2026) & (US$/Unit) Table 148. North America Drugs for the Treatment of Refractory Gout Sales Price by Country (2027-2032) & (US$/Unit) Table 149. United States Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 150. Canada Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 151. Mexico Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 152. Europe Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 155. Europe Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 156. Europe Drugs for the Treatment of Refractory Gout Sales Price by Type (2021-2026) & (US$/Unit) Table 157. Europe Drugs for the Treatment of Refractory Gout Sales Price by Type (2027-2032) & (US$/Unit) Table 158. Europe Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (US$ Million) Table 159. Europe Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (US$ Million) Table 160. Europe Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 161. Europe Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 162. Europe Drugs for the Treatment of Refractory Gout Sales Price by Application (2021-2026) & (US$/Unit) Table 163. Europe Drugs for the Treatment of Refractory Gout Sales Price by Application (2027-2032) & (US$/Unit) Table 164. Europe Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Europe Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 166. Europe Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 167. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 168. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 169. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 170. Europe Drugs for the Treatment of Refractory Gout Sales Price by Country (2021-2026) & (US$/Unit) Table 171. Europe Drugs for the Treatment of Refractory Gout Sales Price by Country (2027-2032) & (US$/Unit) Table 172. Germany Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 173. France Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 174. U.K. Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 175. Italy Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 176. Russia Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 177. Spain Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 178. Netherlands Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 179. Switzerland Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 180. Sweden Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 181. Poland Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 182. China Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (US$ Million) Table 183. China Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (US$ Million) Table 184. China Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 185. China Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 186. China Drugs for the Treatment of Refractory Gout Sales Price by Type (2021-2026) & (US$/Unit) Table 187. China Drugs for the Treatment of Refractory Gout Sales Price by Type (2027-2032) & (US$/Unit) Table 188. China Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (US$ Million) Table 189. China Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (US$ Million) Table 190. China Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 191. China Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 192. China Drugs for the Treatment of Refractory Gout Sales Price by Application (2021-2026) & (US$/Unit) Table 193. China Drugs for the Treatment of Refractory Gout Sales Price by Application (2027-2032) & (US$/Unit) Table 194. Asia Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (US$ Million) Table 195. Asia Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (US$ Million) Table 196. Asia Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 197. Asia Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 198. Asia Drugs for the Treatment of Refractory Gout Sales Price by Type (2021-2026) & (US$/Unit) Table 199. Asia Drugs for the Treatment of Refractory Gout Sales Price by Type (2027-2032) & (US$/Unit) Table 200. Asia Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (US$ Million) Table 201. Asia Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (US$ Million) Table 202. Asia Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 203. Asia Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 204. Asia Drugs for the Treatment of Refractory Gout Sales Price by Application (2021-2026) & (US$/Unit) Table 205. Asia Drugs for the Treatment of Refractory Gout Sales Price by Application (2027-2032) & (US$/Unit) Table 206. Asia Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 207. Asia Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 208. Asia Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 209. Asia Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 210. Asia Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 211. Asia Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 212. Asia Drugs for the Treatment of Refractory Gout Sales Price by Country (2021-2026) & (US$/Unit) Table 213. Asia Drugs for the Treatment of Refractory Gout Sales Price by Country (2027-2032) & (US$/Unit) Table 214. Japan Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 215. South Korea Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 216. India Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 217. Australia Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 218. Taiwan Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 219. Southeast Asia Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 220. SAMEA Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (US$ Million) Table 221. SAMEA Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (US$ Million) Table 222. SAMEA Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 223. SAMEA Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 224. SAMEA Drugs for the Treatment of Refractory Gout Sales Price by Type (2021-2026) & (US$/Unit) Table 225. SAMEA Drugs for the Treatment of Refractory Gout Sales Price by Type (2027-2032) & (US$/Unit) Table 226. SAMEA Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (US$ Million) Table 227. SAMEA Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (US$ Million) Table 228. SAMEA Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 229. SAMEA Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 230. SAMEA Drugs for the Treatment of Refractory Gout Sales Price by Application (2021-2026) & (US$/Unit) Table 231. SAMEA Drugs for the Treatment of Refractory Gout Sales Price by Application (2027-2032) & (US$/Unit) Table 232. SAMEA Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 233. SAMEA Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 234. SAMEA Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 235. SAMEA Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 236. SAMEA Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 237. SAMEA Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 238. SAMEA Drugs for the Treatment of Refractory Gout Sales Price by Country (2021-2026) & (US$/Unit) Table 239. SAMEA Drugs for the Treatment of Refractory Gout Sales Price by Country (2027-2032) & (US$/Unit) Table 240. Brazil Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 241. Argentina Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 242. Chile Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 243. Colombia Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 244. Peru Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 245. Saudi Arabia Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 246. Israel Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 247. UAE Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 248. Turkey Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 249. Iran Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 250. Egypt Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Table 251. Key Raw Materials Table 252. Raw Materials Key Suppliers Table 253. Drugs for the Treatment of Refractory Gout Distributors List Table 254. Drugs for the Treatment of Refractory Gout Customers List Table 255. Research Programs/Design for This Report Table 256. Authors List of This Report Table 257. Secondary Sources Table 258. Primary Sources List of Figures Figure 1. Drugs for the Treatment of Refractory Gout Image Figure 2. Global Drugs for the Treatment of Refractory Gout Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for the Treatment of Refractory Gout Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tumor Necrosis Factor Inhibitors Image Figure 5. PEGylated Recombinant Uricase Image Figure 6. Interleukin Inhibitors Image Figure 7. Other Image Figure 8. Global Drugs for the Treatment of Refractory Gout Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Drugs for the Treatment of Refractory Gout Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital and Clinic Image Figure 11. Retail Pharmacies Image Figure 12. Other Image Figure 13. Global Drugs for the Treatment of Refractory Gout Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 15. Global Drugs for the Treatment of Refractory Gout Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2032) Figure 18. Global Drugs for the Treatment of Refractory Gout Sales (2021-2032) & (K Units) Figure 19. Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Drugs for the Treatment of Refractory Gout Sales YoY (2021-2032) & (K Units) Figure 22. Europe Drugs for the Treatment of Refractory Gout Sales YoY (2021-2032) & (K Units) Figure 23. China Drugs for the Treatment of Refractory Gout Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Drugs for the Treatment of Refractory Gout Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales YoY (2021-2032) & (K Units) Figure 26. Global Drugs for the Treatment of Refractory Gout Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Drugs for the Treatment of Refractory Gout Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032) Figure 32. Global Drugs for the Treatment of Refractory Gout Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032) Figure 35. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032) Figure 38. Global Drugs for the Treatment of Refractory Gout Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032) Figure 41. North America Drugs for the Treatment of Refractory Gout Revenue Share by Type (2021-2032) Figure 42. North America Drugs for the Treatment of Refractory Gout Sales Share by Type (2021-2032) Figure 43. North America Drugs for the Treatment of Refractory Gout Revenue Share by Application (2021-2032) Figure 44. North America Drugs for the Treatment of Refractory Gout Sales Share by Application (2021-2032) Figure 45. North America Drugs for the Treatment of Refractory Gout Revenue Share by Country (2021-2032) Figure 46. North America Drugs for the Treatment of Refractory Gout Sales Share by Country (2021-2032) Figure 47. Europe Drugs for the Treatment of Refractory Gout Revenue Share by Type (2021-2032) Figure 48. Europe Drugs for the Treatment of Refractory Gout Sales Share by Type (2021-2032) Figure 49. Europe Drugs for the Treatment of Refractory Gout Revenue Share by Application (2021-2032) Figure 50. Europe Drugs for the Treatment of Refractory Gout Sales Share by Application (2021-2032) Figure 51. Europe Drugs for the Treatment of Refractory Gout Revenue Share by Country (2021-2032) Figure 52. Europe Drugs for the Treatment of Refractory Gout Sales Share by Country (2021-2032) Figure 53. China Drugs for the Treatment of Refractory Gout Revenue Share by Type (2021-2032) Figure 54. China Drugs for the Treatment of Refractory Gout Sales Share by Type (2021-2032) Figure 55. China Drugs for the Treatment of Refractory Gout Revenue Share by Application (2021-2032) Figure 56. China Drugs for the Treatment of Refractory Gout Sales Share by Application (2021-2032) Figure 57. Asia Drugs for the Treatment of Refractory Gout Revenue Share by Type (2021-2032) Figure 58. Asia Drugs for the Treatment of Refractory Gout Sales Share by Type (2021-2032) Figure 59. Asia Drugs for the Treatment of Refractory Gout Revenue Share by Application (2021-2032) Figure 60. Asia Drugs for the Treatment of Refractory Gout Sales Share by Application (2021-2032) Figure 61. Asia Drugs for the Treatment of Refractory Gout Revenue Share by Country (2021-2032) Figure 62. Asia Drugs for the Treatment of Refractory Gout Sales Share by Country (2021-2032) Figure 63. SAMEA Drugs for the Treatment of Refractory Gout Revenue Share by Type (2021-2032) Figure 64. SAMEA Drugs for the Treatment of Refractory Gout Sales Share by Type (2021-2032) Figure 65. SAMEA Drugs for the Treatment of Refractory Gout Revenue Share by Application (2021-2032) Figure 66. SAMEA Drugs for the Treatment of Refractory Gout Sales Share by Application (2021-2032) Figure 67. SAMEA Drugs for the Treatment of Refractory Gout Revenue Share by Country (2021-2032) Figure 68. SAMEA Drugs for the Treatment of Refractory Gout Sales Share by Country (2021-2032) Figure 69. Drugs for the Treatment of Refractory Gout Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Drugs for the Treatment of Refractory Gout Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Pr

Scope & coverage.

Types
  • Tumor Necrosis Factor Inhibitors
  • PEGylated Recombinant Uricase
  • Interleukin Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Zhuhai Livzon Biotechnology
  • Sobi
  • Qilu Pharmaceutical
  • Roche
  • Bio-Thera Solutions
  • Sandoz
  • Pfizer
  • Novartis
  • Kiniksa Pharmaceuticals
  • Horizo​​n Therapeutics
  • Hanwha Chemical
  • Fresenius Kabi
  • Biogen
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for the Treatment of Refractory Gout Market by Type
  3. 1.2.1 Global Drugs for the Treatment of Refractory Gout Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tumor Necrosis Factor Inhibitors
  5. 1.2.3 PEGylated Recombinant Uricase
  6. 1.2.4 Interleukin Inhibitors
  7. 1.2.5 Other
  8. 1.3 Drugs for the Treatment of Refractory Gout Market by Application
  9. 1.3.1 Global Drugs for the Treatment of Refractory Gout Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital and Clinic
  11. 1.3.3 Retail Pharmacies
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Drugs for the Treatment of Refractory Gout Market Dynamics
  1. 2.1 Drugs for the Treatment of Refractory Gout Industry Trends
  2. 2.2 Drugs for the Treatment of Refractory Gout Industry Drivers
  3. 2.3 Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges
  4. 2.4 Drugs for the Treatment of Refractory Gout Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Drugs for the Treatment of Refractory Gout Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Drugs for the Treatment of Refractory Gout Revenue by Region
  3. 3.2.1 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for the Treatment of Refractory Gout Revenue by Region (2021-2026)
  5. 3.2.3 Global Drugs for the Treatment of Refractory Gout Revenue by Region (2027-2032)
  6. 3.2.4 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Drugs for the Treatment of Refractory Gout Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Drugs for the Treatment of Refractory Gout Sales by Region
  9. 3.4.1 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2026)
  11. 3.4.3 Global Drugs for the Treatment of Refractory Gout Sales by Region (2027-2032)
  12. 3.4.4 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Drugs for the Treatment of Refractory Gout Revenue by Manufacturers
  2. 4.1.1 Global Drugs for the Treatment of Refractory Gout Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Drugs for the Treatment of Refractory Gout Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for the Treatment of Refractory Gout Sales by Manufacturers
  6. 4.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Drugs for the Treatment of Refractory Gout Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Drugs for the Treatment of Refractory Gout Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Drugs for the Treatment of Refractory Gout Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Drugs for the Treatment of Refractory Gout Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Drugs for the Treatment of Refractory Gout Manufacturers, Product Type & Application
  13. 4.7 Global Drugs for the Treatment of Refractory Gout Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Drugs for the Treatment of Refractory Gout Market CR5 and HHI
  16. 4.8.2 2025 Drugs for the Treatment of Refractory Gout Tier 1, Tier 2, and Tier 3
5 Drugs for the Treatment of Refractory Gout Market by Type
  1. 5.1 Global Drugs for the Treatment of Refractory Gout Revenue by Type
  2. 5.1.1 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Drugs for the Treatment of Refractory Gout Sales by Type
  6. 5.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032)
  9. 5.3 Global Drugs for the Treatment of Refractory Gout Price by Type
6 Drugs for the Treatment of Refractory Gout Market by Application
  1. 6.1 Global Drugs for the Treatment of Refractory Gout Revenue by Application
  2. 6.1.1 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Drugs for the Treatment of Refractory Gout Sales by Application
  6. 6.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032)
  9. 6.3 Global Drugs for the Treatment of Refractory Gout Price by Application
7 Company Profiles
  1. 7.1 Zhuhai Livzon Biotechnology
  2. 7.1.1 Zhuhai Livzon Biotechnology Company Information
  3. 7.1.2 Zhuhai Livzon Biotechnology Business Overview
  4. 7.1.3 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio
  6. 7.1.5 Zhuhai Livzon Biotechnology Recent Developments
  7. 7.2 Sobi
  8. 7.2.1 Sobi Company Information
  9. 7.2.2 Sobi Business Overview
  10. 7.2.3 Sobi Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sobi Drugs for the Treatment of Refractory Gout Product Portfolio
  12. 7.2.5 Sobi Recent Developments
  13. 7.3 Qilu Pharmaceutical
  14. 7.3.1 Qilu Pharmaceutical Company Information
  15. 7.3.2 Qilu Pharmaceutical Business Overview
  16. 7.3.3 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio
  18. 7.3.5 Qilu Pharmaceutical Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Roche Drugs for the Treatment of Refractory Gout Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Bio-Thera Solutions
  26. 7.5.1 Bio-Thera Solutions Company Information
  27. 7.5.2 Bio-Thera Solutions Business Overview
  28. 7.5.3 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio
  30. 7.5.5 Bio-Thera Solutions Recent Developments
  31. 7.6 Sandoz
  32. 7.6.1 Sandoz Company Information
  33. 7.6.2 Sandoz Business Overview
  34. 7.6.3 Sandoz Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio
  36. 7.6.5 Sandoz Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Novartis Drugs for the Treatment of Refractory Gout Product Portfolio
  48. 7.8.5 Novartis Recent Developments
  49. 7.9 Kiniksa Pharmaceuticals
  50. 7.9.1 Kiniksa Pharmaceuticals Company Information
  51. 7.9.2 Kiniksa Pharmaceuticals Business Overview
  52. 7.9.3 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio
  54. 7.9.5 Kiniksa Pharmaceuticals Recent Developments
  55. 7.10 Horizo​​n Therapeutics
  56. 7.10.1 Horizo​​n Therapeutics Company Information
  57. 7.10.2 Horizo​​n Therapeutics Business Overview
  58. 7.10.3 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio
  60. 7.10.5 Horizo​​n Therapeutics Recent Developments
  61. 7.11 Hanwha Chemical
  62. 7.11.1 Hanwha Chemical Company Information
  63. 7.11.2 Hanwha Chemical Business Overview
  64. 7.11.3 Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio
  66. 7.11.5 Hanwha Chemical Recent Developments
  67. 7.12 Fresenius Kabi
  68. 7.12.1 Fresenius Kabi Company Information
  69. 7.12.2 Fresenius Kabi Business Overview
  70. 7.12.3 Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio
  72. 7.12.5 Fresenius Kabi Recent Developments
  73. 7.13 Biogen
  74. 7.13.1 Biogen Company Information
  75. 7.13.2 Biogen Business Overview
  76. 7.13.3 Biogen Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Biogen Drugs for the Treatment of Refractory Gout Product Portfolio
  78. 7.13.5 Biogen Recent Developments
  79. 7.14 Amgen
  80. 7.14.1 Amgen Company Information
  81. 7.14.2 Amgen Business Overview
  82. 7.14.3 Amgen Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Amgen Drugs for the Treatment of Refractory Gout Product Portfolio
  84. 7.14.5 Amgen Recent Developments
8 North America
  1. 8.1 North America Drugs for the Treatment of Refractory Gout Market Size by Type
  2. 8.1.1 North America Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  3. 8.1.2 North America Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032)
  4. 8.1.3 North America Drugs for the Treatment of Refractory Gout Price by Type (2021-2032)
  5. 8.2 North America Drugs for the Treatment of Refractory Gout Market Size by Application
  6. 8.2.1 North America Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  7. 8.2.2 North America Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032)
  8. 8.2.3 North America Drugs for the Treatment of Refractory Gout Price by Application (2021-2032)
  9. 8.3 North America Drugs for the Treatment of Refractory Gout Market Size by Country
  10. 8.3.1 North America Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Drugs for the Treatment of Refractory Gout Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for the Treatment of Refractory Gout Market Size by Type
  2. 9.1.1 Europe Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  3. 9.1.2 Europe Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032)
  4. 9.1.3 Europe Drugs for the Treatment of Refractory Gout Price by Type (2021-2032)
  5. 9.2 Europe Drugs for the Treatment of Refractory Gout Market Size by Application
  6. 9.2.1 Europe Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  7. 9.2.2 Europe Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032)
  8. 9.2.3 Europe Drugs for the Treatment of Refractory Gout Price by Application (2021-2032)
  9. 9.3 Europe Drugs for the Treatment of Refractory Gout Market Size by Country
  10. 9.3.1 Europe Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Drugs for the Treatment of Refractory Gout Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Drugs for the Treatment of Refractory Gout Market Size by Type
  2. 10.1.1 China Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  3. 10.1.2 China Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032)
  4. 10.1.3 China Drugs for the Treatment of Refractory Gout Price by Type (2021-2032)
  5. 10.2 China Drugs for the Treatment of Refractory Gout Market Size by Application
  6. 10.2.1 China Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  7. 10.2.2 China Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032)
  8. 10.2.3 China Drugs for the Treatment of Refractory Gout Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for the Treatment of Refractory Gout Market Size by Type
  2. 11.1.1 Asia Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  3. 11.1.2 Asia Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032)
  4. 11.1.3 Asia Drugs for the Treatment of Refractory Gout Price by Type (2021-2032)
  5. 11.2 Asia Drugs for the Treatment of Refractory Gout Market Size by Application
  6. 11.2.1 Asia Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  7. 11.2.2 Asia Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032)
  8. 11.2.3 Asia Drugs for the Treatment of Refractory Gout Price by Application (2021-2032)
  9. 11.3 Asia Drugs for the Treatment of Refractory Gout Market Size by Country
  10. 11.3.1 Asia Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Drugs for the Treatment of Refractory Gout Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for the Treatment of Refractory Gout Market Size by Type
  2. 12.1.1 SAMEA Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Drugs for the Treatment of Refractory Gout Price by Type (2021-2032)
  5. 12.2 SAMEA Drugs for the Treatment of Refractory Gout Market Size by Application
  6. 12.2.1 SAMEA Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Drugs for the Treatment of Refractory Gout Price by Application (2021-2032)
  9. 12.3 SAMEA Drugs for the Treatment of Refractory Gout Market Size by Country
  10. 12.3.1 SAMEA Drugs for the Treatment of Refractory Gout Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Drugs for the Treatment of Refractory Gout Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Drugs for the Treatment of Refractory Gout Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Drugs for the Treatment of Refractory Gout Value Chain Analysis
  2. 13.1.1 Drugs for the Treatment of Refractory Gout Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Drugs for the Treatment of Refractory Gout Production Mode & Process
  6. 13.2 Drugs for the Treatment of Refractory Gout Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Drugs for the Treatment of Refractory Gout Distributors
  9. 13.2.3 Drugs for the Treatment of Refractory Gout Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst